ASCO18: AbbVie blood cancer combo off to a strong start in Phase 2

A combination of AbbVie's blood cancer drugs Imbruvica and Venclexta has delivered high response rates early into a mid-stage study, called CAPTIVATE, of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).